Antifibrotic effect after low-dose imatinib mesylate treatment in patients with nephrogenic systemic fibrosis:an open-label non-randomized, uncontrolled clinical trial

Autor: Elmholdt, T R, Buus, N H, Ramsing, Michele Utke, Olesen, A B

Publikováno v: Elmholdt, T R, Buus, N H, Ramsing, M U & Olesen, A B 2011, ' Antifibrotic effect after low-dose imatinib mesylate treatment in patients with nephrogenic systemic fibrosis : an open-label non-randomized, uncontrolled clinical trial ', Journal of the European Academy of Dermatology and Venereology . https://doi.org/10.1111/j.1468-3083.2011.04398.x

Background Nephrogenic systemic fibrosis is a disease affecting the connective tissue of the skin and internal organs in patients with renal failure. No effective treatments are available. Objectives To investigate if the tyrosine kinase inhibitor, i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pure_au_____::b126fe08968176c8e7f33e588ac8f9fc
https://pure.au.dk/portal/da/publications/antifibrotic-effect-after-lowdose-imatinib-mesylate-treatment-in-patients-with-nephrogenic-systemic-fibrosis(629071a9-8f60-44de-987e-80d3b11520c3).html

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.